TIGIT Antikörper

Produktnummer ABIN2665413

Produktdetails anti-TIGIT Antikörper

Target: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Reaktivität: Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TIGIT Antikörper ist unkonjugiert

Applikation: Intracellular Flow Cytometry (ICFC)

Aufreinigung: The antibody was purified by affinity chromatography.

Klon: 1G9

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TIGIT

Target: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Andere Bezeichnung: TIGIT (TIGIT Produkte)

Synonyme: VSIG9 antikoerper, VSTM3 antikoerper, WUCAM antikoerper, ENSMUSG00000071552 antikoerper, Vstm3 antikoerper, RGD1563191 antikoerper, T-cell immunoreceptor with Ig and ITIM domains antikoerper, T cell immunoreceptor with Ig and ITIM domains antikoerper, TIGIT antikoerper, Tigit antikoerper

Hintergrund: T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as V-set and transmembrane domain-containing protein 3 (Vstm3), is a 26 kD, type I transmembrane protein and member of the CD28 family. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. Its ligands are PVR, PVRL2, PVRL3, CD155, and CD112. TIGIT is a negative regulator of NK and T cell activation. Engagement of TIGIT by dendritic cells results in their differentiation into a tolerogenic phenotype, with an increased secretion of IL-10 and a diminished production of IL-12. Mice deficient for TIGIT are more susceptible to autoimmune disease.

Pathways: Cancer Immune Checkpoints